---
layout: default
title: Vonoprazan
description: "Vonoprazan 的老藥新用潛力分析。高證據等級 L2，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 高證據等級 (L1-L2)
nav_order: 194
evidence_level: L2
indication_count: 10
---

# Vonoprazan

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L2</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Vonoprazan：從糜爛性食道炎到活動性消化性潰瘍

## 一句話總結

<p class="key-answer" data-question="Vonoprazan 可以用於治療什麼新適應症？">
Vonoprazan 原本用於治療糜爛性食道炎、胃潰瘍、十二指腸潰瘍及幽門螺旋桿菌根除。
TxGNN 模型預測它可能對**活動性消化性潰瘍 (active peptic ulcer disease)** 有效，
目前有 **2 個臨床試驗**和 **16 篇文獻**支持這個方向。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 糜爛性食道炎、胃潰瘍、十二指腸潰瘍、幽門螺旋桿菌根除輔助 |
| 預測新適應症 | gastric ulcer (disease)、active peptic ulcer disease、esophagitis (disease)、peptic ulcer perforation、gastrojejunal ulcer、peptic esophagitis、hiatus hernia (disease)、achlorhydria、cascade stomach、gastric dilatation |
| TxGNN 預測分數 | 99.97% |
| 證據等級 | L2 |
| 台灣上市 | 已上市 |
| 許可證數 | 1 張 |
| 建議決策 | Strong Proceed |




## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. active peptic ulcer disease</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.97%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>Vonoprazan 是首創的鉀離子競爭性酸阻斷劑（P-CAB），與傳統質子幫浦抑制劑（PPI）相比，具有以下優勢：</p>
<ul>
<li>抑制 H+,K+-ATPase 的效力約為 Lansoprazole 的 350 倍</li>
<li>不需酸性活化，起效更快</li>
<li>在酸性環境中穩定，持續時間更長</li>
<li>不受 CYP2C19 基因多型性影響</li>

</ul>
<p>這些特性使其在活動性消化性潰瘍的治療中具有明顯優勢。</p>

<h3>臨床試驗</h3>

<table>
<thead>
<tr>
<th>試驗編號</th>
<th>階段</th>
<th>狀態</th>
<th>人數</th>
<th>主要發現</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT03116841">NCT03116841</a></td>
<td>Phase 4</td>
<td>COMPLETED</td>
<td>3</td>
<td>評估 Vonoprazan 20mg 對反流性食道炎患者睡眠障礙的影響</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT03214952">NCT03214952</a></td>
<td>N/A</td>
<td>COMPLETED</td>
<td>3183</td>
<td>評估 Vonoprazan 在胃潰瘍、十二指腸潰瘍和反流性食道炎中的安全性和有效性</td>
</tr>
</tbody>
</table>

<h3>相關文獻</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>年份</th>
<th>類型</th>
<th>期刊</th>
<th>主要發現</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/26369775/">26369775</a></td>
<td>2016</td>
<td>Review</td>
<td>Clin Pharmacokinet</td>
<td>Vonoprazan 藥動學和藥效學特性回顧</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/36660052/">36660052</a></td>
<td>2023</td>
<td>Review</td>
<td>JGH Open</td>
<td>幽門螺旋桿菌感染管理，建議 Vonoprazan 為首選</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/38345252/">38345252</a></td>
<td>2024</td>
<td>Meta-analysis</td>
<td>Am J Gastroenterol</td>
<td>P-CAB vs PPI 治療 Grade C/D 食道炎的系統評價</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/28988197/">28988197</a></td>
<td>2018</td>
<td>RCT</td>
<td>Gut</td>
<td>Vonoprazan 預防 NSAID 相關潰瘍復發，非劣效於 Lansoprazole</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/39156336/">39156336</a></td>
<td>2024</td>
<td>Review</td>
<td>Cureus</td>
<td>Vonoprazan 治療胃酸相關疾病的療效和安全性回顧</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/32998241/">32998241</a></td>
<td>2020</td>
<td>Review</td>
<td>Pharmaceuticals</td>
<td>Vonoprazan 作為幽門螺旋桿菌根除治療的潛在益處</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/28267236/">28267236</a></td>
<td>2017</td>
<td>RCT</td>
<td>Dig Endosc</td>
<td>Vonoprazan 治療內視鏡黏膜下切除術後人工胃潰瘍的效果</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/33620586/">33620586</a></td>
<td>2021</td>
<td>Guideline</td>
<td>J Gastroenterol</td>
<td>日本消化性潰瘍臨床指引 2020，推薦 Vonoprazan</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/39294424/">39294424</a></td>
<td>2024</td>
<td>Meta-analysis</td>
<td>Dig Dis Sci</td>
<td>Vonoprazan vs PPI 治療和預防胃/十二指腸潰瘍的系統評價</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. peptic ulcer perforation</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04728516" target="_blank">NCT04728516</a></td><td>PHASE4</td><td>RECRUITING</td><td>2600</td><td>The Effect of Vonoprazan-based Dual Eradication Therapy vs PPI Treatment on Gast...</td></tr>
</tbody>
</table>

<h3>相關文獻（2 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33620586/" target="_blank">33620586</a></td><td>2021</td><td>Article</td><td>Journal of gastroent</td><td>Evidence-based clinical practice guidelines for peptic ulcer...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39294424/" target="_blank">39294424</a></td><td>2024</td><td>Article</td><td>Digestive diseases a</td><td>Vonoprazan vs. Proton Pump Inhibitors for Treatment and Prev...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. gastrojejunal ulcer</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36228734/" target="_blank">36228734</a></td><td>2023</td><td>Article</td><td>Gastroenterology</td><td>Vonoprazan Versus Lansoprazole for Healing and Maintenance o...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33620586/" target="_blank">33620586</a></td><td>2021</td><td>Article</td><td>Journal of gastroent</td><td>Evidence-based clinical practice guidelines for peptic ulcer...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26369775/" target="_blank">26369775</a></td><td>2016</td><td>Article</td><td>Clinical pharmacokin</td><td>The First-in-Class Potassium-Competitive Acid Blocker, Vonop...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35226174/" target="_blank">35226174</a></td><td>2022</td><td>Article</td><td>Journal of gastroent</td><td>Evidence-based clinical practice guidelines for gastroesopha...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39294424/" target="_blank">39294424</a></td><td>2024</td><td>Article</td><td>Digestive diseases a</td><td>Vonoprazan vs. Proton Pump Inhibitors for Treatment and Prev...</td></tr>
</tbody>
</table>
<p><em>...及其他 15 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. hiatus hernia (disease)</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（6 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41426852/" target="_blank">41426852</a></td><td>2025</td><td>Article</td><td>Cureus</td><td>Vonoprazan Therapy in Gastroesophageal Reflux Disease (GERD)...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38821110/" target="_blank">38821110</a></td><td>2024</td><td>Article</td><td>Scandinavian journal</td><td>The presence of hiatal hernia is a significant predictor for...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41231641/" target="_blank">41231641</a></td><td>2025</td><td>Article</td><td>International journa</td><td>Gastroesophageal reflux disease: comprehensive review from m...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34547219/" target="_blank">34547219</a></td><td>2022</td><td>Article</td><td>Scandinavian journal</td><td>Predictors and timing for the development of symptomatic gas...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36649678/" target="_blank">36649678</a></td><td>2023</td><td>Article</td><td>Digestion</td><td>Examination on Factors Affecting Symptom Change after Drug W...</td></tr>
</tbody>
</table>
<p><em>...及其他 1 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. achlorhydria</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. pylorospasm</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.85%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. Dieulafoy lesion</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.85%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. gastric dilatation</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.85%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（2 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31611534/" target="_blank">31611534</a></td><td>2020</td><td>Article</td><td>Internal medicine (T</td><td>Vonoprazan-associated Gastric Mucosal Redness: A Report of F...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33993429/" target="_blank">33993429</a></td><td>2021</td><td>Article</td><td>Clinical journal of </td><td>Marked reduction in the number of white globe appearance les...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. cascade stomach</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.85%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36343209/" target="_blank">36343209</a></td><td>2023</td><td>Article</td><td>ACS nano</td><td>Endoscopy Deliverable and Mushroom-Cap-Inspired Hyperboloid-...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. hemorrhagic duodenitis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.74%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（5 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33620586/" target="_blank">33620586</a></td><td>2021</td><td>Article</td><td>Journal of gastroent</td><td>Evidence-based clinical practice guidelines for peptic ulcer...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27891632/" target="_blank">27891632</a></td><td>2017</td><td>Article</td><td>Alimentary pharmacol</td><td>Randomised clinical trial: efficacy and safety of vonoprazan...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39712905/" target="_blank">39712905</a></td><td>2025</td><td>Article</td><td>DEN open</td><td>Profound gastric mucosal changes and severe rebound acid hyp...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34085115/" target="_blank">34085115</a></td><td>2021</td><td>Article</td><td>European journal of </td><td>Effect of a proton-pump inhibitor on intestinal microbiota i...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31406072/" target="_blank">31406072</a></td><td>2019</td><td>Article</td><td>Nihon Shokakibyo Gak</td><td>[Refractory eosinophilic gastroenteritis with gastritis, duo...</td></tr>
</tbody>
</table>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 衛部藥輸字（待確認） | 福星定膜衣錠10毫克 | 膜衣錠 | 糜爛性食道炎、胃潰瘍、十二指腸潰瘍、幽門螺旋桿菌根除 |

## 安全性考量

### 藥物交互作用

Vonoprazan 的藥物交互作用相對較少，主要需注意：

| 交互作用類型 | 藥物 | 說明 |
|-------------|------|------|
| 禁忌併用 | Atazanavir、Rilpivirine | 降低抗病毒藥物吸收 |
| 謹慎併用 | Warfarin | 監測 INR |
| 謹慎併用 | Methotrexate | 可能增加血中濃度 |

### 優於 PPI 的安全性特點

- 不受 CYP2C19 基因多型性影響
- 藥效穩定，個體間差異小
- 長期使用的安全性數據持續累積中

## 結論與下一步

**決策：Strong Proceed**

**理由：**
Vonoprazan 對活動性消化性潰瘍的預測與其核准適應症高度重疊，且有大量高品質文獻和臨床試驗支持。作為新一代抑酸劑，其在消化性潰瘍治療中的優越性已獲充分驗證。

**建議：**
- 此預測基本上是對現有適應症的確認和擴展
- 可直接用於臨床實踐，遵循現有用藥指引
- 持續關注長期安全性數據
- 對於 PPI 療效不佳的患者可優先考慮使用


---

## 相關藥物報告

- [Hydroxyurea]({{ "/drugs/hydroxyurea/" | relative_url }}) - 證據等級 L2
- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - 證據等級 L2
- [Acetazolamide]({{ "/drugs/acetazolamide/" | relative_url }}) - 證據等級 L2
- [Oteracil]({{ "/drugs/oteracil/" | relative_url }}) - 證據等級 L2
- [Isosorbide Dinitrate]({{ "/drugs/isosorbide_dinitrate/" | relative_url }}) - 證據等級 L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Vonoprazan老藥新用驗證報告. https://twtxgnn.yao.care/drugs/vonoprazan/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_vonoprazan,
  title = {Vonoprazan老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/vonoprazan/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
